☆ 4.6 Article

Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients

BRITISH JOURNAL OF HAEMATOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia

Petra Langerbeins et al.

Summary: Observation is the standard of care for early-stage asymptomatic chronic lymphocytic leukemia (CLL) patients, as chemotherapy-based interventions have not been effective in prolonging survival. However, early intervention with ibrutinib may lead to superior disease control and is well tolerated. The CLL12 trial showed that ibrutinib significantly improved event-free survival in asymptomatic, treatment-naive early-stage CLL patients at increased risk of progression, without increasing overall toxicity.

BLOOD (2022)

添加到收藏夹

Article Hematology

Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients

Silvia Ramos-Campoy et al.

Summary: This study compared the effectiveness of chromosome banding analysis (CBA) and genomic microarrays (GM) in risk stratification of CLL patients. The results showed moderate agreement between the two methods, but discordant classification in individual cases. Most discrepancies were technique-dependent and no significant correlation in the number of abnormalities was found when different filtering strategies were applied for GM. However, both CBA and GM showed similar predictive values for time to first treatment (TTFT) and overall survival. High complexity defined by both CBA and GM remained significant in the multivariate analysis for TTFT. Validation studies are needed to establish the prognostic value of genome complexity based on GM data in future prospective studies.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Hematology

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

John F. Seymour et al.

Summary: The MURANO trial demonstrated that Venetoclax plus Rituximab is superior to Bendamustine plus Rituximab in terms of progression-free survival and overall survival in relapsed/refractory chronic lymphocytic leukemia (CLL) patients. The study also found that undetectable minimal residual disease (uMRD) can be achieved more often with Venetoclax plus Rituximab, and the long-term implications of uMRD in this treatment regimen were explored.

BLOOD (2022)

添加到收藏夹

Article Oncology

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

Larry Mansouri et al.

Summary: Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. This study assessed the impact of nine recurrently mutated genes in 4580 CLL patients and found that mutations in all genes except MYD88 were associated with significantly shorter time-to-first-treatment. The findings highlight the importance of a compartmentalized approach in identifying high-risk patients, particularly among those with mutated IGHV.

LEUKEMIA (2022)

添加到收藏夹

Article Hematology

Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multicenter study

Alexander C. Leeksma et al.

Summary: Genomic arrays have been shown to be an accurate tool for risk stratification in CLL, with high genomic complexity being an independent adverse prognosticator. Lowering the size cutoff for CNA did not significantly improve risk assessment. Arrays detected more chromosomal abnormalities and performed at least as well as simultaneous chromosome banding analysis for risk stratification.

HAEMATOLOGICA (2021)

添加到收藏夹

Article Hematology

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Gian Matteo Rigolin et al.

BLOOD (2021)

添加到收藏夹

Editorial Material Hematology

Genomic arrays for the identification of high-risk chronic lymphocytic leukemia: ready for prime time?

Antonio Cuneo et al.

HAEMATOLOGICA (2021)

添加到收藏夹

Article Hematology

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

Sameer A. Parikh et al.

Summary: The CLL-IPI is effective in predicting disease progression and survival rates of chronic lymphocytic leukemia patients, with B-cell count being a significant factor in these predictions.

BLOOD (2021)

添加到收藏夹

Article Hematology

The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib

Adam S. Kittai et al.

Summary: In CLL patients treated with ibrutinib, increasing karyotypic complexity was associated with shorter progression-free survival and overall survival. Presence of clonal evolution at progression determined by cytogenetic analysis was predictive of subsequent survival. Further research should explore sequential karyotypic analysis in determining the risk of progression and death in CLL patients.

BLOOD (2021)

添加到收藏夹

Article Oncology

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

William G. Wierda et al.

Summary: The study evaluated the potential for fixed-duration treatment in CLL patients using MRD-guided therapy interruption, with a 95% 1-year DFS rate in placebo randomly assigned patients with Confirmed uMRD suggesting promise for this approach in first-line CLL treatment.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index

Geffen Kleinstern et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

添加到收藏夹

Article Hematology

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Adalgisa Condoluci et al.

BLOOD (2020)

添加到收藏夹

Article Hematology

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact

Panagiotis Baliakas et al.

BLOOD (2019)

添加到收藏夹

Letter Oncology

Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile

I. Del Giudice et al.

LEUKEMIA (2018)

添加到收藏夹

Article Hematology

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek et al.

BLOOD (2018)

添加到收藏夹

Review Oncology

Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia

Kathy Chun et al.

CANCER GENETICS (2018)

添加到收藏夹

Letter Oncology

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

M. A. Hoechstetter et al.

LEUKEMIA (2017)

添加到收藏夹

Letter Hematology

In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI

Gian Matteo Rigolin et al.

BLOOD (2017)

添加到收藏夹

Article Oncology

Guidelines for genomic array analysis in acquired haematological neoplastic disorders

Jacqueline Schoumans et al.

GENES CHROMOSOMES & CANCER (2016)

添加到收藏夹

Article Oncology

Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations

Gian Matteo Rigolin et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)

添加到收藏夹

Article Oncology

An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data

Michael Hallek

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Chromosome Aberrations Detected by Conventional Karyotyping Using Novel Mitogens in Chronic Lymphocytic Leukemia: Clinical and Biologic Correlations

Gian Matteo Rigolin et al.

GENES CHROMOSOMES & CANCER (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Database of Genomic Variants: a curated collection of structural variation in the human genome

Jeffrey R. MacDonald et al.

NUCLEIC ACIDS RESEARCH (2014)

添加到收藏夹

Article Oncology

Genomic arrays in chronic lymphocytic leukemia routine clinical practice: are we ready to substitute conventional cytogenetics and fluorescence in situ hybridization techniques?

Anna Puiggros et al.

LEUKEMIA & LYMPHOMA (2013)

添加到收藏夹

Meeting Abstract Hematology

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia - First Results Of a Randomized German-French Cooperative Phase III Trial

Carmen D. Schweighofer et al.

BLOOD (2013)

添加到收藏夹

Article Hematology

Brief report Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with normal FISH: correlations with clinicobiologic parameters

Gian Matteo Rigolin et al.

BLOOD (2012)

添加到收藏夹

Article Hematology

High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations

Jennifer Edelmann et al.

BLOOD (2012)

添加到收藏夹

Article Hematology

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia

Peter Ouillette et al.

BLOOD (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.